Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ash, G.
Right arrow Articles by Tomenson, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ash, G.
Right arrow Articles by Tomenson, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 959-967
© 1999 British Society for Rheumatology

The effects of dothiepin on subjects with rheumatoid arthritis and depression

G. Ash, C. M. Dickens1, F. H. Creed1, M. I. V. Jayson2 and B. Tomenson1

Department of Psychiatry, Ormskirk and District General Hospital, Wigan Road, Ormskirk, Lancashire L39 2AZ,
1 Department of Psychiatry, University of Manchester, Rawnsley Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 and
2 Rheumatic Diseases Centre, University of Manchester Clinical Sciences Building, Hope Hospital, Eccles Old Road, Salford M6 8HD, UK

Correspondence to: G. Ash.

Background. The relative importance of direct analgesic and antidepressant effects of antidepressant drugs in rheumatoid arthritis (RA) is not clear.

Method. Forty-eight female out-patients with RA, with depression and/or anxiety, were entered into a double-blind, placebo-controlled study of dothiepin in doses up to 150 mg daily to assess the effects on mood [Hospital Anxiety and Depression (HAD) scale and Hamilton Rating Scale (HRS) for Depression], pain [visual analogue scale (VAS)] and disability [Health Assessment Questionnaire (HAQ)].

Results. Repeated measures multivariate analysis of variance revealed that treatment had a significant effect on pain (Fd.f. 1,39 =5.7, P=0.02). There were further interaction effects between treatment and time on pain (Fd.f. 3,117 =3.3, P=0.03), disability (Fd.f. 3,117=4.2, P=0.008) and duration of early morning stiffness (Fd.f. 3,117 =3.3, P=0.03). Depression (HRS) was considerably reduced in both the dothiepin and placebo groups, and there was no significant difference between groups. Post hoc analyses using analysis of covariance revealed that, in the dothiepin group, pain was significantly reduced by week 4 and remained so at week 12. Disability scores and duration of early morning stiffness were consistently lower in the dothiepin group, although differences failed to reach statistical significance at any follow-up assessment. In the group as a whole, reductions in pain were highly significantly correlated with reductions in HAD depression (r =0.63, P<0.0005), HAD anxiety (r=0.46, P=0.001) and HRS depression (r=0.37, P=0.01).

Conclusion. Dothiepin is effective in relieving pain, disability and reducing the duration of early morning stiffness in out-patients with RA. Although there is a general association between pain reduction and improved anxiety and depression, the analgesic effect of dothiepin is independent of its antidepressant effect. Individual variation is considerable and further research should try to identify mechanisms of interaction between the antidepressant and analgesic effects of treatment in different patient groups.

KEY WORDS: Rheumatoid arthritis, Depression, Anxiety, Treatment, Dothiepin, Analgesia, Antidepressant effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
S. Perrot, R.-M. Javier, M. Marty, C. Le Jeunne, F. Laroche, and the CEDR (Cercle d'Etude de la Douleur en Rhumatol
Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies
Rheumatology, August 1, 2008; 47(8): 1117 - 1123.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. H. B. Lin, W. Katon, M. Von Korff, L. Tang, J. W. Williams Jr, K. Kroenke, E. Hunkeler, L. Harpole, M. Hegel, P. Arean, et al.
Effect of Improving Depression Care on Pain and Functional Outcomes Among Older Adults With Arthritis: A Randomized Controlled Trial
JAMA, November 12, 2003; 290(18): 2428 - 2429.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
C. Dickens, J. Jackson, B. Tomenson, E. Hay, and F. Creed
Association of Depression and Rheumatoid Arthritis
Psychosomatics, June 1, 2003; 44(3): 209 - 215.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. J. Chuck, A. J. Swannell, A. O. House, R. Pownall, G. Ash, C. M. Dickens, and F. H. Creed
The effects of dothiepin on subjects with rheumatoid arthritis and depression
Rheumatology, December 1, 2000; 39(12): 1425 - 1427.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.